Compare 10X Genomics Inc (TXG) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Value Index Fund ETF — how do they compare? 10X Genomics Inc trades at $81 (market cap $10.07B), while Vanguard Value Index Fund ETF trades at $220.47 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 26.1× 10X Genomics Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 3,293,281). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| TXG | VTV | |
|---|---|---|
Market Cap | $10.07B | $262.40B |
Volume | 5,657,286 | 3,293,281 |
Sector | Health | — |
52-Week High | $97.74 | $227.51 |
52-Week Low | $11.48 | $182.86 |
Typical Hold Time | 91 Days | 142 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
VTV trades at $220.55, up 1.07% with a bearish technical signal despite bullish moving averages. The ETF shows institutional accumulation with recent purchases by QRG Capital Management and Blue Edge Capital. Recent news highlights value stocks outperforming growth in 2026, with VTV's 2.3% yield and low 0.03% fee attracting income-focused investors amid market rotation from tech.
The outlook remains mixed—technical indicators suggest near-term pressure, but strong institutional interest and value stock momentum support long-term stability. Key risks include underperformance versus broad market indices and sensitivity to interest rate changes. The dividend yield provides income cushion, yet investors should weigh VTV's value tilt against broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
